Remove Cannabis Remove DEA Remove Safety Remove Treatment
article thumbnail

DEA Approves Cocaine Derivative for Parkinson’s Research. Why Not Cannabis?

Veriheal

As cannabis enthusiasts, we’re all too familiar with the stigma surrounding its use and the hoops that have to be jumped through to get it into medical research trials. But recent news of the DEA’s approval of a cocaine derivative for Parkinson’s disease research has left us scratching our heads. So what gives?

DEA 98
article thumbnail

Court: DEA Must Explain Its Failure to Act Upon Pending Marijuana Cultivation Applications

NORML

.” To date, however, the agency has neither affirmed or denied any of the 26 applicants that have sought the DEA’s permission for a federal cultivation license. Read NORML’s new op-ed, “Three years ago the DEA said they would remove roadblocks to cannabis research — they still haven’t, here.).

DEA 227
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Judge Grants Hearing for Opposition to DEA Proposal to Criminalize 5 More Psychedelics

Cannabis Law Report

A 28-page DEA report — authored in August of 2021, and based on Department of Health and Human Services reviews of these psychedelics from 2012 — states, “These five tryptamines have no known medical use in the United States and are not marketed internationally as approved drug products. Read full report at.

DEA 52
article thumbnail

DEA Approves MMJ International Holdings THC Shipment for Multiple Sclerosis, Huntington’s Disease Drug Development

Cannabis Law Report

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ will be utilizing its new products for an FDA approved treatment of multiple sclerosis (MS) and Huntington’s disease (HD). Orphan Drug Designation?

DEA 66
article thumbnail

The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?

Freedom Leaf

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. schedules were created by the Controlled Substances Act (CSA) in 1970 and are interpreted and enforced by the DEA.

DEA 51
article thumbnail

Psilocybin-Alcohol Study, FDA’s Psychedelic Guide, & the NCAA’s Cannabis Overhaul Begins

Veriheal

A study investigated psilocybin’s effect on alcohol addiction, the FDA outlined best practices for future psychedelic research, and the NCAA is inching toward cannabis policy change. Additionally, participants also reported feeling increased self-awareness and general improvement in relationships following their treatment.

article thumbnail

A Proposed Social Media Drug Reporting Bill Raises Privacy Concerns

Veriheal

A disputable new social media drug reporting bill believes that social media companies should screen client posts and report any drug-related exercises to the DEA. As they work to enhance public safety, elected officers should live unwavering in their obligation to staunchly defend the proper privacy and freedom of expression online.

Media 52